A Phase 1 interventional study of Comparator: [18F]-FDG PET/CT and Volumetric CT in Advanced Pancreatic Adenocarcinoma, sponsored by Merck Sharp & Dohme LLC. Terminated. Open to participants aged 35 Years and older. Per ClinicalTrials.gov, last updated 2015-07-27.
Sponsored by Merck Sharp & Dohme LLC · Phase 1, Interventional, and Diagnostic
This study will determine whether [18F]-fluorodeoxyglucose-positron emission tomography (FDG-PET) can be used to screen for the activity of novel pancreatic cancer treatments.
2,004 studies on the registry are indexed under Adenocarcinoma; 375 are open to participants now.
This study's enrollment of 15 is below the median of 45 across 1,553 interventional studies indexed under Adenocarcinoma.
Browse Adenocarcinoma studies →Merck Sharp & Dohme LLC is the lead sponsor of 2,114 studies on the registry; 133 are open to participants now.
Of its 489 completed or terminated interventional studies of FDA-regulated products, 362 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
\[18F\]-FDG-PET/CT (Computed Tomography) Imaging
Procedure: Comparator: [18F]-FDG PET/CT and Volumetric CT
Patients will receive gemcitabine-based therapy as prescribed by their treating physician. FDG-PET/CT scans will be performed at baseline following enrollment, and after 3 and 6-7 weeks of therapy. Volumetric CT scans will be performed at baseline following enrollment, and after 3 and 6-7 weeks of therapy.
Association of changes in FDG uptake with overall survival (OS)
Time frame: Week 3 and at least 7 months after the last patient is treated
Association of metabolic response with OS
Time frame: Baseline, Week 3, and at least 7 months after the last patient is treated
Correlation between FDG standardized uptake values (SUV) at Week 3 and Week 6-7
Time frame: Week 3 and Week 6-7
No study locations are listed for this record.
This study is terminated, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Merck Sharp & Dohme LLC